Jamie Harrop

1.9k total citations
8 papers, 170 citations indexed

About

Jamie Harrop is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Jamie Harrop has authored 8 papers receiving a total of 170 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 2 papers in Genetics and 2 papers in Oncology. Recurrent topics in Jamie Harrop's work include Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (2 papers) and Peptidase Inhibition and Analysis (2 papers). Jamie Harrop is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (2 papers) and Peptidase Inhibition and Analysis (2 papers). Jamie Harrop collaborates with scholars based in United States, United Kingdom and Germany. Jamie Harrop's co-authors include Akshay Vaishnaw, Verena Karsten, Daniel P. Judge, Pushkal Garg, Xiaoping Zhang, Arnt V. Kristen, Marianne T. Sweetser, Martha Grogan, Joshua R. Vest and Mathew S. Maurer and has published in prestigious journals such as Circulation, Journal of Hypertension and Value in Health.

In The Last Decade

Jamie Harrop

8 papers receiving 169 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jamie Harrop United States 5 153 41 26 25 24 8 170
Emily Brown United States 7 147 1.0× 41 1.0× 31 1.2× 5 0.2× 28 1.2× 15 169
Amanda M. Campbell United States 4 117 0.8× 25 0.6× 19 0.7× 4 0.2× 4 0.2× 6 155
Neil Auricchio United States 4 112 0.7× 63 1.5× 14 0.5× 3 0.1× 8 0.3× 6 229
Martha Imprialou United Kingdom 3 117 0.8× 13 0.3× 13 0.5× 4 0.2× 4 0.2× 4 201
Yue Ren China 7 61 0.4× 126 3.1× 21 0.8× 7 0.3× 4 0.2× 16 180
Sandra Schordan Germany 6 92 0.6× 15 0.4× 8 0.3× 6 0.2× 3 0.1× 7 179
Rebecca Morgan United States 6 43 0.3× 24 0.6× 24 0.9× 10 0.4× 3 0.1× 7 136
Xufen Cao China 8 87 0.6× 9 0.2× 7 0.3× 5 0.2× 27 1.1× 15 149
О. В. Головенко Russia 2 85 0.6× 40 1.0× 17 0.7× 7 0.3× 2 0.1× 4 169
Cong Ye China 7 98 0.6× 55 1.3× 23 0.9× 6 0.2× 4 0.2× 15 289

Countries citing papers authored by Jamie Harrop

Since Specialization
Citations

This map shows the geographic impact of Jamie Harrop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamie Harrop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamie Harrop more than expected).

Fields of papers citing papers by Jamie Harrop

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jamie Harrop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamie Harrop. The network helps show where Jamie Harrop may publish in the future.

Co-authorship network of co-authors of Jamie Harrop

This figure shows the co-authorship network connecting the top 25 collaborators of Jamie Harrop. A scholar is included among the top collaborators of Jamie Harrop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jamie Harrop. Jamie Harrop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
2.
Huang, Stephen A., Jörg Täubel, Giuseppe Fiore, et al.. (2021). SAFETY, PHARMACODYNAMICS, AND BLOOD PRESSURE EFFECTS OF ALN-AGT, AN RNA INTERFERENCE THERAPEUTIC TARGETING ANGIOTENSINOGEN, IN A RANDOMIZED SINGLE ASCENDING DOSE STUDY OF HYPERTENSIVE ADULTS. Journal of Hypertension. 39(Supplement 1). e8–e8. 5 indexed citations
3.
Judge, Daniel P., Arnt V. Kristen, Martha Grogan, et al.. (2020). Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovascular Drugs and Therapy. 34(3). 357–370. 80 indexed citations
4.
Judge, Daniel P., Arnt V. Kristen, Martha Grogan, et al.. (2020). Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovascular Drugs and Therapy. 34(6). 889–889. 49 indexed citations
5.
6.
Adams, David, Teresa Coelho, Brian R. Bettencourt, et al.. (2015). Burden of Illness for Patients with familial amyloidotic Polyneuropathy (Fap) Begins Early and Increases with Disease Progression. Value in Health. 18(3). A287–A287. 1 indexed citations
7.
Adams, David, Teresa Coelho, Ole B. Suhr, et al.. (2013). Interim results from phase ii trial of aln-ttr02, a novel RNAi therapeutic for the treatment of familial amyloidotic polyneuropathy. Journal of the Peripheral Nervous System. 18. 1–2. 2 indexed citations
8.
Zimmermann, Tracy, Verena Karsten, Jamie Harrop, et al.. (2013). Phase I First-in-Humans Trial of ALN-TTRsc, a Novel RNA Interference Therapeutic for the Treatment of Familial Amyloidotic Cardiomyopathy (FAC). Journal of Cardiac Failure. 19(8). S66–S66. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emily Brown Breakdown of academic impact, for papers by Amanda M. Campbell Breakdown of academic impact, for papers by Neil Auricchio Breakdown of academic impact, for papers by Martha Imprialou Breakdown of academic impact, for papers by Yue Ren Breakdown of academic impact, for papers by Sandra Schordan Breakdown of academic impact, for papers by Rebecca Morgan Breakdown of academic impact, for papers by Xufen Cao Breakdown of academic impact, for papers by О. В. Головенко Breakdown of academic impact, for papers by Cong Ye
Rankless by CCL
2026